Baxter and Momenta $33m collaboration on biosimilars
This article was originally published in Scrip
Executive Summary
Baxter and Momenta have entered into a global collaboration to develop and commercialise biosimilars, with Baxter paying $33 million upfront for up to six follow-on biologic compounds.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.